Immune Checkpoint Inhibitors

Category: technique

Monoclonal antibodies that block PD-1, PD-L1, or CTLA-4 immune checkpoints, releasing the brakes on anti-tumor immune responses. Revolutionary in oncology.

Mechanism Detail

PD-1 (on T cells) binds PD-L1 (on tumor cells) to suppress anti-tumor immunity. Anti-PD-1 (nivolumab, pembrolizumab) and anti-PD-L1 (atezolizumab) antibodies block this interaction, reactivating exhausted T cells. CTLA-4 inhibitors (ipilimumab) act earlier in T cell activation. Combinations and sequencing strategies are intensely studied.

Clinical Status

FDA-approved for 15+ cancer types. Response rates 15-40% as monotherapy. Combination with Anktiva, chemotherapy, or radiation improves outcomes. Biomarker-driven patient selection (PD-L1, TMB, MSI-H) is standard.

Relevant Diseases

• Stage IV Cancer

Relevant Therapies

• Anktiva
• Cell-Based Therapies

Related Terms

• PD-1
• PD-L1
• Anktiva
• Tumor microenvironment